Year All2024202320222021202020192018201720152014 Nov 20, 2024 CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting Nov 12, 2024 CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates Nov 11, 2024 CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer Aug 30, 2024 CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Aug 08, 2024 CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates Jun 18, 2024 CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec Jun 06, 2024 CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC May 24, 2024 CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting May 09, 2024 CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates May 03, 2024 Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Nov 20, 2024 CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Nov 11, 2024 CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
Aug 30, 2024 CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Jun 06, 2024 CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
May 24, 2024 CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 03, 2024 Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer